

**FEDERAL RESERVE SYSTEM****Formations of, Acquisitions by, and Mergers of Bank Holding Companies**

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than November 21, 1997.

**A. Federal Reserve Bank of Cleveland** (Jeffery Hirsch, Banking Supervisor) 1455 East Sixth Street, Cleveland, Ohio 44101-2566:

1. *Strasburg Bancorp, Inc.*, Strasburg, Ohio; to become a bank holding company by acquiring 100 percent of the voting shares of Strasburg Savings, Strasburg, Ohio (in formation).

**B. Federal Reserve Bank of San Francisco** (Pat Marshall, Manager of Analytical Support, Consumer Regulation Group) 101 Market Street, San Francisco, California 94105-1579:

1. *Timberland Bancorp, Inc.*, Hoquiam, Washington; to become a bank holding company by acquiring 100 percent of the voting shares of Timberland Savings Bank, SSB, Hoquiam, Washington.

Board of Governors of the Federal Reserve System, October 22, 1997.

**Jennifer J. Johnson,**

*Deputy Secretary of the Board.*

[FR Doc. 97-28423 Filed 10-24-97; 8:45 am]

BILLING CODE 6210-01-F

**FEDERAL RESERVE SYSTEM****Formations of, Acquisitions by, and Mergers of Bank Holding Companies; Correction**

This notice corrects a notice (FR Doc. 97-27636) published on pages 54460 - 54461 of the issue for Monday, October 20, 1997.

Under the Federal Reserve Bank of Richmond heading, the entry for NationsBank Corporation, and NB Holdings Corporation, both of Charlotte, North Carolina, is revised to read as follows:

**A. Federal Reserve Bank of Richmond** (A. Linwood Gill III, Assistant Vice President) 701 East Byrd Street, Richmond, Virginia 23261-4528:

1. *NationsBank Corporation, and NB Holdings Corporation*, both of Charlotte, North Carolina; to merge with Barnett Banks, Inc., Jacksonville, Florida, and thereby indirectly acquire Barnett Bank, National Association, Jacksonville, Florida, and Community Bank of the Islands, Sanibel, Florida.

In connection with this application, Applicants also have applied to acquire First of America Bank - Florida, FSB, Tampa, Florida, and thereby engage in traditional thrift activities, pursuant to § 225.28(b)(4) of the Board's Regulation Y; Barnett Community Development Corporation, Jacksonville, Florida, and thereby engage in investing in corporations or projects designed primarily to promote community welfare, pursuant to § 225.28(b)(12) of the Board's Regulation Y; EquiCredit Corporation, Jacksonville, Florida, and its direct and indirect subsidiaries, and thereby engage in the activities of originating home equity and purchase money loans, acquiring such loans originated from third parties, and securitizing such loans in the secondary market, pursuant to § 225.28(b)(1) of the Board's Regulation Y, and in acting as principal, agent, or broker for credit related insurance, pursuant to § 225.28(b)(11) of the Board's Regulation Y; Equity/Protect Reinsurance Company, Jacksonville, Florida, and thereby engage in the activities of reinsuring credit related insurance policies sold to EquiCredit Corporation customers, pursuant to § 225.28(b)(11) of the Board's Regulation Y; and Honor Technologies, Inc., Maitland, Florida, and thereby engage in operating an electronic funds transfer network and in data processing and management consulting activities, pursuant to §§ 225.28(b)(9) and (b)(14), respectively of the Board's Regulation Y.

In connection with this proposal, NationsBank has applied to acquire an

option for 19.9 percent of Barnett's outstanding shares. Barnett also has applied to acquire an option for 10 percent of the shares of NationsBank Corporation and all of its bank and nonbanking subsidiaries. These options will expire upon consummation of the merger.

Comments on this application must be received by November 13, 1997.

Board of Governors of the Federal Reserve System, October 22, 1997.

**Jennifer J. Johnson,**

*Deputy Secretary of the Board.*

[FR Doc. 97-28424 Filed 10-24-97; 8:45 am]

BILLING CODE 6210-01-F

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration**

[Docket No. 97D-0420]

**Guidance for Industry on OTC Treatment of Hypercholesterolemia; Availability**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of a guidance document entitled "OTC Treatment of Hypercholesterolemia." The guidance is intended to clarify the agency's current thinking on the treatment of hypercholesterolemia using over-the-counter (OTC) drug products. The agency's Center for Drug Evaluation and Research (CDER) believes that drugs for the treatment of hypercholesterolemia should not be sold OTC in the United States.

**DATES:** Written comments may be submitted at any time.

**ADDRESSES:** Submit written requests for single copies of the guidance "OTC Treatment of Hypercholesterolemia" to the Drug Information Branch (HFD-210), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send one self-addressed adhesive label to assist that office in processing your requests. Submit written comments on the guidance to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:** Michael Weintraub, Center for Drug Evaluation and Research (HFD-105), Food and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857, 301-827-2250.

**SUPPLEMENTARY INFORMATION:** FDA is announcing the availability of a guidance for industry entitled "OTC Treatment of Hypercholesterolemia." Several sponsors have recently expressed interest in marketing cholesterol-lowering agents as OTC drug products. These requests have raised several regulatory policy and medical therapy issues.

This guidance document represents the agency's current thinking on OTC treatment of hypercholesterolemia. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such an approach satisfies the requirement of the applicable statute, regulations, or both.

Interested persons may, at any time, submit written comments on the guidance to the Dockets Management Branch (address above). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The guidance and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain

the guidance by using the World Wide Web (WWW). For WWW access, go to "http://www.fda.gov/cder/guidance/index.htm".

Dated: October 17, 1997.

**William K. Hubbard,**  
Associate Commissioner for Policy Coordination.

[FR Doc. 97-28298 Filed 10-24-97; 8:45 am]

BILLING CODE 4160-01-F

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Proposed Collection; Comment Request; Treatment Observation's Study**

**SUMMARY:** In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

**PROPOSED COLLECTION:** The Treatment Research Branch (TRB), intends to conduct the study for "Treatment Observation". The TRB is authorized by

Section 452 of Part G of Title IV of the Public Health Service Act (42 U.S.C. 288) as amended by the NIH Revitalization Act of 1993 (Pub. L. 103-43).

The information proposed for collection will be used by the NIAAA to observe group treatment at up to 20 treatment facilities. At each facility, directors will be asked to provide information about treatment practices and about the client population. At each facility at least seven members of the treatment staff will be asked to provide information about their treatment activities, personal experiences and training. At each facility eight treatment groups will be observed. The group leader will be asked to complete a questionnaire about the observed session and other client demographics. At least seven group members will also be asked to complete a questionnaire about the observed group session. The target population for the study is a group of outpatient public and private providers that will include group treatment as part of their overall plan of clinical therapeutics.

The specific aim of this study is the testing of instruments and methodologies for the systematic measurement of the content, process, and context of group treatment.

The annual burden estimates are as follows:

Type and number of respondents	Responses per respondent	Total responses	Hours	Total hours
Facility Director—20 .....	1	20	.75	15
Group Leader—160 .....	1	160	.334	55
Treatment Staff—140 .....	1	140	.334	48
Group Member—1120 .....	1	1120	.334	381
Total Number of Respondents .....		1440		
Total Number of Responses .....		1440		
Total Hours .....		499		

**REQUEST FOR COMMENTS:** Comments are invited on: (a) Whether the proposed collection is necessary, including whether the information has practical use; (b) ways to enhance the clarity, quality, and use of the information to be collected; (c) the accuracy of the agency estimate of burden of the proposed collection; and (d) ways to minimize the collection burden of the respondents. Send written comments to Dr. Margaret Mattson, Treatment Research Branch, Division of Clinical and Prevention Research (DCPR), NIAAA, NIH, Willco Building 6000, Room 505, 6000 Executive Boulevard, Bethesda, Maryland 20892-7003.

**FOR FURTHER INFORMATION CONTACT:**

To request more information on the proposed project or to obtain a copy of the data collection plans, contact Dr. Margaret Mattson, Treatment Research Branch, Division of Clinical and Prevention Research (DCPR), NIAAA, NIH, 6000 Willco Building, Room 505, 6000 Executive Boulevard, Bethesda, Maryland 20892-7003, or call non-toll-free number (301) 443-0638.

**COMMENTS DUE DATE:** Comments regarding this information collection are best assured of having their full effect if received within 60-days of the date of this publication.

Dated: October 20, 1997.

**Martin K. Trusty,**  
Executive Officer, NIAAA.  
[FR Doc. 97-28382 Filed 10-24-97; 8:45 am]  
BILLING CODE 4140-01-M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Center for Scientific Review; Notice of Closed Meetings**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice